These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

262 related items for PubMed ID: 12740572

  • 1. Attenuation of levodopa-induced dyskinesia by normalizing dopamine D3 receptor function.
    Bézard E, Ferry S, Mach U, Stark H, Leriche L, Boraud T, Gross C, Sokoloff P.
    Nat Med; 2003 Jun; 9(6):762-7. PubMed ID: 12740572
    [Abstract] [Full Text] [Related]

  • 2. Motor response to a dopamine D3 receptor preferring agonist compared to apomorphine in levodopa-primed 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Chase TN.
    J Pharmacol Exp Ther; 1997 Nov; 283(2):794-9. PubMed ID: 9353400
    [Abstract] [Full Text] [Related]

  • 3. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease.
    Visanji NP, Fox SH, Johnston T, Reyes G, Millan MJ, Brotchie JM.
    Neurobiol Dis; 2009 Aug; 35(2):184-92. PubMed ID: 19118628
    [Abstract] [Full Text] [Related]

  • 4. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with\ increased motor disability.
    Iravani MM, Tayarani-Binazir K, Chu WB, Jackson MJ, Jenner P.
    J Pharmacol Exp Ther; 2006 Dec; 319(3):1225-34. PubMed ID: 16959959
    [Abstract] [Full Text] [Related]

  • 5. Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates.
    Smith LA, Jackson MJ, Johnston L, Kuoppamaki M, Rose S, Al-Barghouthy G, Del Signore S, Jenner P.
    Clin Neuropharmacol; 2006 Dec; 29(3):112-25. PubMed ID: 16772809
    [Abstract] [Full Text] [Related]

  • 6. Differential effect of selective D-1 and D-2 dopamine receptor agonists on levodopa-induced dyskinesia in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine- exposed monkeys.
    Blanchet P, Bédard PJ, Britton DR, Kebabian JW.
    J Pharmacol Exp Ther; 1993 Oct; 267(1):275-9. PubMed ID: 7901395
    [Abstract] [Full Text] [Related]

  • 7. Antiparkinsonian effects of the novel D3/D2 dopamine receptor agonist, S32504, in MPTP-lesioned marmosets: Mediation by D2, not D3, dopamine receptors.
    Hill MP, Ravenscroft P, McGuire SG, Brotchie JM, Crossman AR, Rochat C, Millan MJ.
    Mov Disord; 2006 Dec; 21(12):2090-5. PubMed ID: 16991143
    [Abstract] [Full Text] [Related]

  • 8. Selective blockade of D(3) dopamine receptors enhances the anti-parkinsonian properties of ropinirole and levodopa in the MPTP-lesioned primate.
    Silverdale MA, Nicholson SL, Ravenscroft P, Crossman AR, Millan MJ, Brotchie JM.
    Exp Neurol; 2004 Jul; 188(1):128-38. PubMed ID: 15191809
    [Abstract] [Full Text] [Related]

  • 9. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 10. Effect of D1 and D2 agonists and antagonists on dyskinesia produced by L-dopa in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys.
    Gomez-Mancilla B, Bédard PJ.
    J Pharmacol Exp Ther; 1991 Oct; 259(1):409-13. PubMed ID: 1681090
    [Abstract] [Full Text] [Related]

  • 11. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH, Henry B, Hill M, Crossman A, Brotchie J.
    Mov Disord; 2002 Nov; 17(6):1180-7. PubMed ID: 12465055
    [Abstract] [Full Text] [Related]

  • 12. S32504, a novel naphtoxazine agonist at dopamine D3/D2 receptors: II. Actions in rodent, primate, and cellular models of antiparkinsonian activity in comparison to ropinirole.
    Millan MJ, Di Cara B, Hill M, Jackson M, Joyce JN, Brotchie J, McGuire S, Crossman A, Smith L, Jenner P, Gobert A, Peglion JL, Brocco M.
    J Pharmacol Exp Ther; 2004 Jun; 309(3):921-35. PubMed ID: 14978195
    [Abstract] [Full Text] [Related]

  • 13. Effects of piclozotan (SUN N4057), a partial serotonin 1A receptor agonist, on motor complications induced by repeated administration of levodopa in parkinsonian rats.
    Tani Y, Ogata A, Koyama M, Inoue T.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):218-23. PubMed ID: 20858480
    [Abstract] [Full Text] [Related]

  • 14. Pathogenesis of levodopa-induced dyskinesia: focus on D1 and D3 dopamine receptors.
    Guigoni C, Aubert I, Li Q, Gurevich VV, Benovic JL, Ferry S, Mach U, Stark H, Leriche L, Håkansson K, Bioulac BH, Gross CE, Sokoloff P, Fisone G, Gurevich EV, Bloch B, Bezard E.
    Parkinsonism Relat Disord; 2005 Jun 15; 11 Suppl 1():S25-9. PubMed ID: 15885624
    [Abstract] [Full Text] [Related]

  • 15. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys.
    Blanchet PJ, Konitsiotis S, Whittemore ER, Zhou ZL, Woodward RM, Chase TN.
    J Pharmacol Exp Ther; 1999 Sep 15; 290(3):1034-40. PubMed ID: 10454475
    [Abstract] [Full Text] [Related]

  • 16. Actions at sites other than D(3) receptors mediate the effects of BP897 on l-DOPA-induced hyperactivity in monoamine-depleted rats.
    Visanji NP, Millan MJ, Brotchie JM.
    Exp Neurol; 2006 Nov 15; 202(1):85-92. PubMed ID: 16814282
    [Abstract] [Full Text] [Related]

  • 17. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: effect on adenosine A2A receptors.
    Morissette M, Dridi M, Calon F, Hadj Tahar A, Meltzer LT, Bédard PJ, Di Paolo T.
    Synapse; 2006 Sep 01; 60(3):239-50. PubMed ID: 16739115
    [Abstract] [Full Text] [Related]

  • 18. The partial dopamine agonist pardoprunox (SLV308) administered in combination with l-dopa improves efficacy and decreases dyskinesia in MPTP treated common marmosets.
    Tayarani-Binazir K, Jackson MJ, Rose S, McCreary AC, Jenner P.
    Exp Neurol; 2010 Dec 01; 226(2):320-7. PubMed ID: 20843474
    [Abstract] [Full Text] [Related]

  • 19. Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys.
    Blanchet PJ, Calon F, Martel JC, Bédard PJ, Di Paolo T, Walters RR, Piercey MF.
    J Pharmacol Exp Ther; 1995 Feb 01; 272(2):854-9. PubMed ID: 7853204
    [Abstract] [Full Text] [Related]

  • 20. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC, Jackson MJ, Rose S, McCreary AC, Jenner P.
    Mov Disord; 2010 Oct 15; 25(13):2059-66. PubMed ID: 20721904
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.